To build upon our findings on dual Axl and MerTK inhibition to treat HNSCC, we collaborated with Incyte Pharmaceuticals to obtain a novel kinase inhibitor, INCB08INCB081776 (INCB081776), targeting both Axl and MerTK [69]. This evidence concerns the gene AXL and head and neck squamous cell carcinoma.